
|Articles|December 3, 2012
FDA approves cabozantinib to treat rare type of thyroid cancer
FDA has approved cabozantinib (Cometriq, Exelixis and AstraZeneca) for the treatment of progressive, metastatic medullary thyroid cancer (MTC).
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
How PBMs Legally Challenged Arkansas’ Pharmacy Ownership Law | NCPA 2025
2
COVID-19 Vaccination Benefits Patients With Systemic Lupus Erythematosus
3
General Awareness of PBM Practices Driving Optimism for Independent Pharmacies | NCPA 2025
4
FDA Releases Biosimilar Guidance Pushing to Streamline Development
5

























































































































































